Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

Health CarePharmaceuticals & Biotechnology
  • Price (USD)2.49
  • Today's Change0.00 / 0.00%
  • Shares traded44.00
  • 1 Year change22.06%
  • Beta1.3324
Data delayed at least 15 minutes, as of Jan 28 2020 21:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.

  • Revenue in USD (TTM)81.75m
  • Net income in USD-46.47m
  • Incorporated1996
  • Employees160.00
  • Location
    Rigel Pharmaceuticals Inc1180 Veterans BlvdSOUTH SAN FRANCISCO 94080-1985United StatesUSA
  • Phone+1 (650) 624-1100
  • Fax+1 (650) 624-1101
  • Websitehttps://www.rigel.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Urovant Sciences Ltd0.00-109.64m396.45m39.00--16.61-----3.62-3.620.000.78190.00----0.00-223.03---344.03-------------79.600.6465-------200.65------
Osmotica Pharmaceuticals PLC245.82m-350.08m397.50m466.00--2.49--1.62-9.15-9.155.432.720.36434.734.61527,503.60-51.88---60.60--49.14---142.42--1.78-0.72820.6544--7.31---165.90------
AnaptysBio Inc5.00m-94.07m397.78m78.00--0.9438--79.56-3.49-3.490.185415.530.0103--1.9364,102.56-19.30-13.42-20.36-14.43-----1,881.34-150.34----0.0073---50.00-1.83-105.04--95.73--
Fulcrum Therapeutics Inc0.00-85.36m406.13m62.00--3.84-----3.83-3.830.004.53------0.00--------------------0.0005-------54.30------
Atreca Inc0.00-59.36m407.71m102.00--2.52-----2.19-
Fast Line Holding Inc0.00-342.94k411.93m-----------0.0033-0.00330.00-0.00230.00-------68.89---380.60-------------2,906.582.83------89.79------
Progenics Pharmaceuticals, Inc.23.10m-71.98m413.96m79.00--7.40--17.92-0.8452-0.84520.27130.64730.1479--3.85292,379.80-46.08-18.78-52.20-20.4459.61---311.63-97.69---33.810.4225--33.5414.72-23.66--42.92--
Rigel Pharmaceuticals, Inc.81.75m-46.47m417.35m160.00--6.06--5.11-0.2777-0.27770.4890.41110.58551.0711.03517,373.40-33.28-54.09-40.67-64.5398.88---56.84-338.024.03--0.1244--892.6244.159.63---1.96--
SIGA Technologies, Inc.24.05m49.65m421.59m41.008.384.108.4217.530.62020.62020.29431.270.13870.513310.11586,520.0028.644.4730.124.6992.70--206.487.428.03-0.34330.4341--3,788.30143.971,183.35---34.64--
Dynavax Technologies Corporation29.97m-159.08m423.52m249.00--10.82--14.13-2.40-2.400.44950.46690.11150.71835.80120,349.40-57.99-63.29-67.82-72.6537.91---519.95-1,627.744.09-11.840.8194--2,407.03-6.14-66.99--56.28--
Aptorum Group Ltd596.58k-18.43m424.78m39.00--17.03--712.03-0.1303-0.13030.0210.8590.01835.401.2815,296.92-58.12---77.17---11.72---3,224.87--12.91-1.980.0069-------482.22------
BioSpecifics Technologies Corp.36.28m23.30m425.39m5.0018.293.6417.7611.733.173.174.9415.930.3422--2.257,255,512.0021.9820.9022.2621.46----64.2347.08----0.000.0020.1117.9661.3530.56----
Corbus Pharmaceuticals Holdings Inc35.50m-62.18m430.72m77.00--14.53--12.13-1.02-1.020.56320.45830.549----461,004.50-96.17-93.35-151.96-122.99-----175.17-1,216.46----0.00--97.62---71.71------
Beyondspring Inc0.00-38.13m431.76m52.00--19.64-----1.62-1.620.000.7886------0.00-------------------159.570.0591------40.21------
Voyager Therapeutics Inc73.73m-53.55m435.98m123.00--4.00--5.91-1.63-1.632.102.940.2572----599,390.30-18.68-34.85-23.13-38.94-----72.64-497.22----0.00---24.82---24.88------
Inovio Pharmaceuticals Inc6.34m-114.66m436.05m281.00--12.82--68.83-1.18-1.180.06490.34020.0434--3.5122,544.70-78.96-39.71-95.28-49.23-----1,821.08-203.75---19.610.6599---27.8017.75-9.93--63.78--
Data as of Jan 28 2020. Currency figures normalised to Rigel Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

58.11%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Sep 201923.33m13.92%
Wellington Management Co. LLPas of 30 Sep 201922.00m13.13%
BlackRock Fund Advisorsas of 30 Sep 201913.07m7.80%
Millennium Management LLCas of 13 Nov 20198.76m5.22%
The Vanguard Group, Inc.as of 30 Sep 20198.00m4.77%
Tamarack Advisers LPas of 30 Sep 20195.48m3.27%
Invesco Advisers, Inc.as of 30 Sep 20195.00m2.98%
Rock Springs Capital Management LPas of 30 Sep 20194.20m2.51%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 20193.81m2.28%
Citadel Advisors LLCas of 30 Sep 20193.76m2.24%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.